Immunome, Inc.IMNMNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank29
3Y CAGR+12.8%
5Y CAGR-31.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+12.8%/yr
Annual compound
5Y CAGR
-31.2%/yr
Recent acceleration
Percentile
P29
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 32.81% |
| 2024 | 67.65% |
| 2023 | 44.23% |
| 2022 | 22.85% |
| 2021 | 132.34% |
| 2020 | 213.11% |
| 2019 | 76.10% |
| 2018 | 0.00% |